While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...